Welcome to our dedicated page for MARIMED SEC filings (Ticker: MRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MariMed Inc. filings document formal disclosures for a cannabis consumer products and retail operator, including annual-meeting governance, operating results and material capital-structure agreements. Recent Form 8-K reports furnish quarterly and annual financial results and describe the restructuring of the company's Series B Convertible Preferred Stock obligation, including related debt and equity components.
Proxy materials disclose stockholder meeting procedures and board-governance matters. The filings also identify MariMed's emerging growth company status and provide public records for transactions, obligations and reporting events connected to its cannabis brand, wholesale distribution and dispensary operations.
MariMed Inc. director Edward J. Gildea received 192,308 restricted stock units on July 15, 2026 as part of his board fees, granted in lieu of cash. These RSUs vested immediately and converted one-for-one into 192,308 common shares at no cash cost, increasing his direct holdings to 1,172,516 shares and leaving no RSUs outstanding from this award.
MariMed Inc. reports that Chief Commercial Officer Ryan Crandall exercised 250,000 Restricted Stock Units into common stock on June 15, 2026, from a December 15, 2025 RSU grant. To cover tax obligations, 86,626 shares were withheld at $0.069 per share. Following these transactions, he directly holds 1,102,803 common shares, with remaining RSUs under this grant scheduled to vest in equal installments on December 15, 2026, June 15, 2027 and December 15, 2027.
MARIMED INC. director Eva Selhub, M.D. exercised 75,000 Restricted Stock Units (RSUs) into the same number of shares of common stock. This was recorded as a derivative exercise, not an open‑market purchase or sale. After the transaction, she directly holds 557,671 shares of common stock. The RSUs converted to common stock on a one-for-one basis and this grant, originally awarded on June 12, 2025, is now fully exhausted under its award agreement.
MariMed Inc. director Edward J. Gildea exercised restricted stock units into common shares. On June 12, 2026, 75,000 RSUs converted into 75,000 shares of common stock on a one-for-one basis at no cash exercise price. This exhausted the June 12, 2025 RSU grant, and Gildea now holds 980,208 common shares directly.
MARIMED INC. director David R. Allen exercised restricted stock units into common shares. He converted 75,000 RSUs into 75,000 shares of common stock at a stated price of $0.0000 per share. After this transaction, he holds 551,144 common shares directly. The RSUs were originally granted on June 12, 2025 and have now been fully settled, with no units remaining under that grant.
MariMed Inc. Chief Commercial Officer Ryan Crandall reported compensation-related equity activity. He exercised 54,000 Restricted Stock Units (RSUs), which converted into an equal number of common shares. In connection with this vesting, 18,711 common shares were withheld by MariMed to cover tax obligations, rather than sold on the open market. Following these transactions, Crandall directly holds 939,429 shares of MariMed common stock, reflecting a routine RSU vesting and associated tax-withholding disposition.
Gildea Edward J reported acquisition or exercise transactions in this Form 4 filing.
MariMed Inc. director Edward J. Gildea reported new equity compensation. On June 4, 2026, he was granted 75,000 Restricted Stock Units (RSUs), each convertible into one share of common stock. The RSUs vest in full one year from the grant date. Following this filing, he directly holds 905,208 shares of common stock and a separate award of 75,000 RSUs.
MariMed Inc. director Allen David R reported a new equity award rather than an open-market trade. On June 4, he received 75,000 Restricted Stock Units (RSUs), which each convert into one share of common stock on a one-for-one basis.
The RSUs will vest in full one year from the grant date under his award agreement. After this filing, he directly holds 476,144 shares of common stock and a separate position of 75,000 RSUs, highlighting a compensation-related grant instead of a buy or sell in the market.
MARIMED INC. director Eva Selhub, M.D. reported a compensation-related equity award. She received 75,000 Restricted Stock Units (RSUs), which are a form of stock-based compensation, at a grant price of $0.00 per unit.
According to the footnotes, these RSUs convert into common stock on a one-for-one basis and will vest in full one year from the grant date, based on the award agreement between the company and Selhub. The filing also shows she directly holds 482,671 shares of common stock following the reported transactions. This Form 4 reflects an equity grant rather than any open-market share purchase or sale.
MariMed Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 4, 2026. Stockholders re-elected four directors—Jon R. Levine, Edward Gildea, David Allen, and Eva Selhub, M.D.—to serve until the next annual meeting or until successors are elected and qualified.
Stockholders also approved, on an advisory basis, the appointment of M&K CPAs PLLC as MariMed’s independent auditors for the 2026 fiscal year, with a substantial majority of votes cast in favor.